Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
10.19
-0.07 (-0.68%)
At close: May 7, 2026, 4:00 PM EDT
10.36
+0.17 (1.67%)
After-hours: May 7, 2026, 7:12 PM EDT
Arvinas Revenue
In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%. Arvinas had revenue of $9.50M in the quarter ending December 31, 2025, a decrease of -83.95%.
Revenue (ttm)
$262.60M
Revenue Growth
-0.30%
P/S Ratio
2.48
Revenue / Employee
$1,067,480
Employees
246
Market Cap
651.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.86K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Zevra Therapeutics | 122.29M |
| Gyre Therapeutics | 117.05M |
| Sutro Biopharma | 102.48M |
| Aclaris Therapeutics | 8.37M |
ARVN News
- 2 days ago - Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - GlobeNewsWire
- 3 days ago - Arvinas management to meet with BTIG - TheFly
- 3 days ago - Arvinas price target raised to $24 from $21 at Citi - TheFly
- 6 days ago - Arvinas gets early approval for Vepdeg, says Truist - TheFly
- 6 days ago - Arvinas trading resumes - TheFly
- 6 days ago - Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC - TheFly
- 6 days ago - Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 6 days ago - US FDA approves Pfizer, Arvinas' breast cancer drug - Reuters